MARKET

TENX

TENX

Tenax Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5802
-0.0084
-1.43%
Closed 16:00 05/25 EDT
OPEN
0.6000
PREV CLOSE
0.5886
HIGH
0.6000
LOW
0.5800
VOLUME
8.38K
TURNOVER
2.13K
52 WEEK HIGH
2.300
52 WEEK LOW
0.5001
MARKET CAP
14.63M
P/E (TTM)
-0.2853
1D
5D
1M
3M
1Y
5Y
BRIEF-Tenax Therapeutics Files Prospectus Related To Resale Of Up To 21.2 Million Shares Of Common Stock By Certain Selling Stockholders - SEC Filing
reuters.com · 14h ago
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
MORRISVILLE, N.C., May 25, 2022--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, t...
Business Wire · 23h ago
TENX: 1Q:22 Financial and Operational Review
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
Benzinga · 1d ago
Tenax Therapeutics Discloses Completion of Study of TNX-201 for Pulmonary Arterial Hypertension
MT Newswires · 2d ago
Tenax Therapeutics Reports Successful Comparative Pharmacokinetic Study Of Co.'s TNX-201 For Treatment Of Pulmonary Arterial Hypertension
TNX-201 (oral imatinib modified release tablets) Formulation Development has been Successfully Completed Manufacturing Underway to Support Phase 3 PAH Study (IMPROVE) MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax
Benzinga · 2d ago
Tenax therapeutics announces $8M PIPE offering
Tenax Therapeutics (NASDAQ:TENX) enters into a agreement with a single institutional investor for the issuance and sale of 10,596,027 units at a purchase price of $0.755/unit. Each Unit consists of one
Seekingalpha · 05/18 13:00
BRIEF-Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
reuters.com · 05/18 12:32
Tenax Therapeutics Announces $8M PIPE Offering Priced At-The-Market under Nasdaq Rules
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,
Benzinga · 05/18 12:32
More
No Data
Learn about the latest financial forecast of TENX. Analyze the recent business situations of Tenax Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TENX stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
High5.00
Average4.500
Low4.000
Current 0.5802
EPS
Actual
Estimate
-1.31-0.98-0.66-0.33
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 45
Institutional Holdings: 8.11M
% Owned: 32.19%
Shares Outstanding: 25.21M
TypeInstitutionsShares
Increased
6
393.59K
New
4
13.38K
Decreased
4
25.57K
Sold Out
2
30.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Non-Executive Chairman/Independent Director
Gerald Proehl
President/Chief Executive Officer/Director
Christopher Giordano
Chief Financial Officer
Eliot Lurier
Other/Director
Stuart Rich
Independent Director
June Almenoff
Independent Director
Steven Boyd
Independent Director
Michael Davidson
Independent Director
Delcan Doogan
Independent Director
Robyn Hunter
Independent Director
I. Keith Maher
No Data
No Data
About TENX
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases of unmet medical need. The Company's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The Company's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). It is also developing an oral formulation of imatinib mesylate, a kinase inhibitor, for the treatment of pulmonary arterial hypertension (PAH).

Webull offers kinds of Tenax Therapeutics Inc stock information, including NASDAQ:TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.